Kronik Hepatit C Genotip 1 de Güncel Tedavi
Yıl: 2018 Cilt: 25 Sayı: 4 Sayfa Aralığı: 547 - 551 Metin Dili: Türkçe DOI: 10.5505/vtd.2018.14890 İndeks Tarihi: 25-02-2020
Kronik Hepatit C Genotip 1 de Güncel Tedavi
Öz: Hepatit C virüsü (HCV) hem akut, hem de kronik hepatitesebep olur. Akut enfeksiyondan sonra hastaların yaklaşık%80’inde kronik enfeksiyon gelişir. Kronik hepatit C (KHC)yıllar içinde ilerleyici bir seyir izleyerek siroz, hepatosellülerkarsinom (HCC) veya karaciğer transplantasyonu ilesonuçlanabilir. Dünyada karaciğer transplantasyonunun en sıknedenleri arasında yer alır. Son zamanlarda KHC tedavisindeveren baş döndürücü gelişmeler olmuştur. Yeni gelişmelerle%90 -95 in üzerinde başarı oranı sağlanmış olması gelecek içinümit vericidir.
Anahtar Kelime: Konular:
Current Treatment of Chronic Hepatitis C Genotype 1
Öz: Hepatitis C virus (HCV) causes both acute and chronic hepatitis. Following acute HCV infection, chronic infection develops in about %80 of patients. In years, Chronic hepatitis C(CHC) can progress to cirrhosis, hepatocellular carcinoma (HCC) or may result in liver transplantation. It is one of the most common causes of liver transplantion in the world. Recently, the treatment of CHC has dramatically improved. The success rate of over 90-95% with new developments in treatment, is promising for the future.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- He L F, Alling D, Popkin T et al. Determining the size of nonA non-B hepatitis by filtration. JInfect Dis 1987 ;156:636-640
- Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. Best Pract Res Clin Gastroenterol 2012;26:371-80.
- 3-Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4): 1333-42.
- Manns MP, McHutchson JG, Gordon SC et al.PEGPEG-interferon Alfa-2B plus ribavirin compared to interferon Alfa-2B plus Ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65
- Lawitz E1, Poordad FF2, Pang PS et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial: Lancet. 2014 Feb 8;383(9916):515-23. doi: 10.1016/S0140-6736(13)62121-2. Epub 2013 Nov 5.
- Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889.
- Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383:515.
- Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146:736.
- Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594.
- Poordad F, Hezode C, Trinh R, et al. ABT-450/rombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973.
- Ferenci P, Bernstein D, Lalezari J, et al. ABT- 450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983.
- Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatmentnaive patients: the COSMOS randomised study. Lancet 2014; 384:1756.
- Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology 2015; 148:762.
- Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. January 2014 http://www.hcvguidelines.org/ (Accessed on January 01, 2015).
- European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63:199.
- Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483.
- Poordad F, Hezode C, Trinh R, et al. ABT-450/rombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973.
- Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604.
- Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147:359.
- Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, doubleblind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15:397.
- Reddy KR, Bourlière M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 2015; 62:79.
- Osinusi A, Kohli A, Marti MM, et al. Retreatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med 2014; 161:634.
- Wyles D, Pockros P, Morelli G, et al. Ledipasvirsofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015; 61:1793.
| APA | AYDIN M, DÜLGER A (2018). Kronik Hepatit C Genotip 1 de Güncel Tedavi. , 547 - 551. 10.5505/vtd.2018.14890 |
| Chicago | AYDIN MESUT,DÜLGER Ahmet Cumhur Kronik Hepatit C Genotip 1 de Güncel Tedavi. (2018): 547 - 551. 10.5505/vtd.2018.14890 |
| MLA | AYDIN MESUT,DÜLGER Ahmet Cumhur Kronik Hepatit C Genotip 1 de Güncel Tedavi. , 2018, ss.547 - 551. 10.5505/vtd.2018.14890 |
| AMA | AYDIN M,DÜLGER A Kronik Hepatit C Genotip 1 de Güncel Tedavi. . 2018; 547 - 551. 10.5505/vtd.2018.14890 |
| Vancouver | AYDIN M,DÜLGER A Kronik Hepatit C Genotip 1 de Güncel Tedavi. . 2018; 547 - 551. 10.5505/vtd.2018.14890 |
| IEEE | AYDIN M,DÜLGER A "Kronik Hepatit C Genotip 1 de Güncel Tedavi." , ss.547 - 551, 2018. 10.5505/vtd.2018.14890 |
| ISNAD | AYDIN, MESUT - DÜLGER, Ahmet Cumhur. "Kronik Hepatit C Genotip 1 de Güncel Tedavi". (2018), 547-551. https://doi.org/10.5505/vtd.2018.14890 |
| APA | AYDIN M, DÜLGER A (2018). Kronik Hepatit C Genotip 1 de Güncel Tedavi. Van Tıp Dergisi, 25(4), 547 - 551. 10.5505/vtd.2018.14890 |
| Chicago | AYDIN MESUT,DÜLGER Ahmet Cumhur Kronik Hepatit C Genotip 1 de Güncel Tedavi. Van Tıp Dergisi 25, no.4 (2018): 547 - 551. 10.5505/vtd.2018.14890 |
| MLA | AYDIN MESUT,DÜLGER Ahmet Cumhur Kronik Hepatit C Genotip 1 de Güncel Tedavi. Van Tıp Dergisi, vol.25, no.4, 2018, ss.547 - 551. 10.5505/vtd.2018.14890 |
| AMA | AYDIN M,DÜLGER A Kronik Hepatit C Genotip 1 de Güncel Tedavi. Van Tıp Dergisi. 2018; 25(4): 547 - 551. 10.5505/vtd.2018.14890 |
| Vancouver | AYDIN M,DÜLGER A Kronik Hepatit C Genotip 1 de Güncel Tedavi. Van Tıp Dergisi. 2018; 25(4): 547 - 551. 10.5505/vtd.2018.14890 |
| IEEE | AYDIN M,DÜLGER A "Kronik Hepatit C Genotip 1 de Güncel Tedavi." Van Tıp Dergisi, 25, ss.547 - 551, 2018. 10.5505/vtd.2018.14890 |
| ISNAD | AYDIN, MESUT - DÜLGER, Ahmet Cumhur. "Kronik Hepatit C Genotip 1 de Güncel Tedavi". Van Tıp Dergisi 25/4 (2018), 547-551. https://doi.org/10.5505/vtd.2018.14890 |
